AIM ImmunoTech announces Phase 2 study of Ampligen open, recruiting patients

AIM ImmunoTech announced that the AMP-270 Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer, LAPC, has opened its first clinical site and has begun recruiting patients. Thomas Equels, M.S., J.D., Chief Executive Officer of AIM ImmunoTech, commented, "We continue to believe that Ampligen and the AMP-270 study have the potential to establish a much-needed new standard of care for LAPC where there remains a significant unmet need. Our team continues to execute on advancing this important study forward and we are pleased that the first of our sites is open for recruitment. We are working closely with preeminent cancer institutions across the United States and Europe to build momentum toward the commencement of patient enrollment and dosing and look forward to achieving those milestones as soon as possible."